Streetbeat News

Revenues

IPGP

IPG Photonics has provided guidance for Q4 2024, expecting revenue between $210M and $240M, and adjusted EPS between $0.05 and $0.35, compared to estimates of $228.45M and $0.20 respectively. The guidance excludes Russian operations sold in Q3.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 12:03 pm

SYY

Sysco has reiterated its guidance for the fiscal year 2025, indicating confidence in its future performance and strategic plans.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 12:02 pm

SYY

Sysco's Q1 2025 earnings per share missed estimates, but sales exceeded expectations. EPS was $1.09, below the $1.13 estimate, while sales were $20.5 billion, surpassing the $20.463 billion estimate.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 12:01 pm

ON

Analysts have mixed views on ON Semiconductor (NASDAQ:ON) with recent ratings showing a slight negative shift in sentiment. The average 12-month price target is $82.75, down by 2.65%. The company faces challenges with a -17.15% revenue decline but shows strong profitability and financial health.

Portfolio Pulse from Benzinga Insights

October 29, 2024 | 12:01 pm

ECL

Ecolab reported Q3 2024 earnings per share of $1.83, slightly beating the estimate of $1.82. However, sales were $4.00 billion, missing the $4.04 billion estimate. Sales increased by 1.02% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 12:01 pm

ALKT

Analysts have shown a positive shift in sentiment towards Alkami Technology (NASDAQ:ALKT), with several raising their price targets and ratings. The average 12-month price target has increased by 17.8% to $37.86. Alkami Technology, a cloud-based digital banking solutions provider, has shown strong revenue growth but faces challenges with profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

October 29, 2024 | 12:01 pm

PFE

Pfizer reported strong Q3 earnings with a significant increase in revenue and profit, driven by high demand for its COVID-19 products, Paxlovid and Comirnaty. The company raised its 2024 revenue and EPS guidance, expecting $10 billion from COVID products.

Portfolio Pulse from Vandana Singh

October 29, 2024 | 12:01 pm

NBIX

The article provides an in-depth analysis of 20 analyst recommendations for Neurocrine Biosciences (NASDAQ:NBIX) over the past three months. Analysts have varied opinions, with ratings ranging from bullish to bearish. The average 12-month price target has increased slightly to $161.9. Neurocrine Biosciences is a pharmaceutical company with strong financial metrics, including a 30.37% revenue growth rate and a net margin of 11.01%.

Portfolio Pulse from Benzinga Insights

October 29, 2024 | 12:00 pm

THC

Tenet Healthcare Corporation (THC) has provided guidance for Q4, expecting net operating revenues between $5.007 billion and $5.207 billion, which is below the estimated $5.29 billion. The adjusted EPS is projected to be between $2.69 and $3.31, compared to the estimated $2.88.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 11:59 am

CROX

SHPH

VFC

Shuttle Pharmaceuticals (SHPH) shares surged 91% after finalizing agreements for Phase 2 clinical trials. VF Corporation (VFC) shares rose 23% following better-than-expected Q2 results. Crocs (CROX) shares fell 12% due to disappointing Q3 results and lowered revenue guidance for the HEYDUDE brand.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 11:58 am